LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has ...

GlaxoSmithKline CEO Andrew Witty is still counting on new respiratory meds to help pull the company out of the financial doldrums, and he has a new inhaler plant in ...

This is the eighth FDA clearance Propeller Health has received for its respiratory therapy platform. Propeller had previously earned the CE Mark in Europe and approval by Health Canada to sell the ...

Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe. It is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

Incruse Ellipta Inhaler Approved for COPD GlaxoSmithKline announced that the FDA has approved Incruse Ellipta (umeclidinium) inhaler for the long-term, once-daily, maintenance treatment of airflow ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...

The more researchers know about patient adherence to drugs, the better they can adapt products to keep patients compliant--which, in turn, helps pad sales. Makers of ...

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...